Servier licenses GLPG1972 in osteoarthritis from Galapagos - Seite 2
About Servier
Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 148 countries and a
turnover of 4 billion euros in 2016, Servier employs 21,000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generic drugs) in research and development and
uses all its profits for development. Corporate growth is driven by Servier's constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric
disease, oncology and diabetes, as well as by its activities in high-quality generic drugs.
Becoming a key player in the fight against immune-inflammatory disease is part of Servier's long-term strategy. Servier wishes to bring innovative therapeutic solutions to patients suffering from
these often highly debilitating pathologies. Its research focuses on lupus, Gougerot-Sjögren syndrome and scleroderma, for which no cure exists. This goal will be reached by establishing
partnerships all over the world, in order to accelerate the marketing of innovative drugs with high added value for patients.
More information: www.servier.com
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline
comprises a pipeline of Phase 3, Phase 2, Phase 1, pre-clinical, and discovery programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. We have discovered and
developed filgotinib: in collaboration with Gilead we aim to bring this JAK1-selective inhibitor for inflammatory indications to patients all over the world. Galapagos is focused on the development
and commercialization of novel medicines that will improve people's lives. The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 550 employees, operating from its
Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia. More information at www.glpg.com.
Contact Servier
Karine Bousseau
Servier External Communications
Tel: +33 1 5572 4021 /+33 6.49.92.16.05
media@servier.com
Contact Galapagos
Investors:
Elizabeth Goodwin
VP IR & Corporate Communications
+1 781 460 1784
Lesen Sie auch
Paul van der Horst
Director IR & Business Development
+31 6 53 725 199
ir@glpg.com